{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:10:05Z","timestamp":1751688605623,"version":"3.41.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-025-01090-1","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T17:08:48Z","timestamp":1749229728000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors Impacting the Immunogenicity of Etrolizumab &amp; Clinical Consequences"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6223-8201","authenticated-orcid":false,"given":"Gizette","family":"Sperinde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yenny","family":"Webb-Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zicheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashis","family":"Saha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Eden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanna","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhian","family":"Jacob-Moffatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ketevan","family":"Siradze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Van","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saloumeh K.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"issue":"1","key":"1090_CR1","first-page":"46","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, et al. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time. Based on Systematic Review Gastroenterology. 2012;142(1):46-54.e42.","journal-title":"Based on Systematic Review Gastroenterology"},{"issue":"10114","key":"1090_CR2","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2018","unstructured":"Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769\u201378.","journal-title":"Lancet"},{"issue":"1","key":"1090_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1146\/annurev-immunol-030409-101225","volume":"28","author":"A Kaser","year":"2010","unstructured":"Kaser A, Zeissig S, Blumberg RS. Inflammatory Bowel Disease. Annu Rev Immunol. 2010;28(1):573\u2013621.","journal-title":"Annu Rev Immunol"},{"issue":"Supplement_2","key":"1090_CR4","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1093\/jcag\/gwad015","volume":"6","author":"SK Murthy","year":"2023","unstructured":"Murthy SK, et al. The 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape. J Can Assoc Gastroenterol. 2023;6(Supplement_2):S97\u2013110.","journal-title":"J Can Assoc Gastroenterol."},{"issue":"1","key":"1090_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/ecco-jcc\/jjx117","volume":"12","author":"P Hindryckx","year":"2018","unstructured":"Hindryckx P, et al. The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients? J Crohn\u2019s Colitis. 2018;12(1):105\u201319.","journal-title":"J Crohn\u2019s Colitis"},{"key":"1090_CR6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.phrs.2015.07.005","volume":"100","author":"G Rogler","year":"2015","unstructured":"Rogler G. Where are we heading to in pharmacological IBD therapy? Pharmacol Res. 2015;100:220\u20137.","journal-title":"Pharmacol Res"},{"issue":"11","key":"1090_CR7","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/apt.14631","volume":"47","author":"MT Tang","year":"2018","unstructured":"Tang MT, et al. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-\u03b27 integrin therapy for inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47(11):1440\u201352.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1090_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(21)00338-1","volume":"7","author":"DT Rubin","year":"2022","unstructured":"Rubin DT, et al. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol. 2022;7(1):17\u201327.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"1090_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S2468-1253(21)00295-8","volume":"7","author":"S Vermeire","year":"2022","unstructured":"Vermeire S, et al. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol. 2022;7(1):28\u201337.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"1090_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2468-1253(21)00298-3","volume":"7","author":"L Peyrin-Biroulet","year":"2022","unstructured":"Peyrin-Biroulet L, et al. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2022;7(2):128\u201340.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"1090_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S2468-1253(21)00294-6","volume":"7","author":"S Danese","year":"2022","unstructured":"Danese S, et al. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol Hepatol. 2022;7(2):118\u201327.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"1090_CR12","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","volume":"16","author":"G Shankar","year":"2014","unstructured":"Shankar G, et al. Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides\u2014Harmonized Terminology and Tactical Recommendations. AAPS J. 2014;16(4):658\u201373.","journal-title":"AAPS J"},{"key":"1090_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3389\/fimmu.2020.00589","volume":"11","author":"P Mehta","year":"2020","unstructured":"Mehta P, Manson JJ. What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis? Front Immunol. 2020;11:589.","journal-title":"Front Immunol"},{"issue":"9940","key":"1090_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","volume":"384","author":"S Vermeire","year":"2014","unstructured":"Vermeire S, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384(9940):309\u201318.","journal-title":"Lancet"},{"issue":"6","key":"1090_CR15","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/jcph.649","volume":"56","author":"X Wei","year":"2016","unstructured":"Wei X, et al. Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis. J Clin Pharmacol. 2016;56(6):693\u2013704.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"1090_CR16","doi-asserted-by":"publisher","first-page":"e1003348","DOI":"10.1371\/journal.pmed.1003348","volume":"17","author":"S H\u00e4ssler","year":"2020","unstructured":"H\u00e4ssler S, et al. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Med. 2020;17(10):e1003348.","journal-title":"PLoS Med"},{"issue":"4","key":"1090_CR17","doi-asserted-by":"publisher","first-page":"e0195325","DOI":"10.1371\/journal.pone.0195325","volume":"13","author":"M Liu","year":"2018","unstructured":"Liu M, et al. Identification of HLA-DRB1 association to adalimumab immunogenicity. PLoS ONE. 2018;13(4):e0195325.","journal-title":"PLoS ONE"},{"issue":"1","key":"1090_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","volume":"158","author":"A Sazonovs","year":"2020","unstructured":"Sazonovs A, et al. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn\u2019s Disease. Gastroenterology. 2020;158(1):189\u201399.","journal-title":"Gastroenterology"},{"issue":"3","key":"1090_CR19","doi-asserted-by":"publisher","first-page":"e90479","DOI":"10.1371\/journal.pone.0090479","volume":"9","author":"J Link","year":"2014","unstructured":"Link J, et al. Human Leukocyte Antigen Genes and Interferon Beta Preparations Influence Risk of Developing Neutralizing Anti-Drug Antibodies in Multiple Sclerosis. PLoS ONE. 2014;9(3):e90479.","journal-title":"PLoS ONE"},{"issue":"6","key":"1090_CR20","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/cts.13264","volume":"15","author":"C Hammer","year":"2022","unstructured":"Hammer C, et al. Allelic variation in HLA-DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro. Clin Transl Sci. 2022;15(6):1393\u20139.","journal-title":"Clin Transl Sci"},{"key":"1090_CR21","doi-asserted-by":"crossref","unstructured":"Saha A, McCarthy MI, Fischer SK, Sperinde G, Hammer C. HLA Class II Alleles are associated with Anti-Drug Antibodies in Ulcerative Colitis Patients Treated with Etrolizumab. medRxiv. 2025.","DOI":"10.1101\/2025.03.28.25320486"},{"issue":"9","key":"1090_CR22","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/psp4.12846","volume":"11","author":"A Moein","year":"2022","unstructured":"Moein A, Lu T, Jonsson S, et al. Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis. CPT Pharmacometrics Syst Pharmacol. 2022;11(9):1244\u201355.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1090_CR23","unstructured":"Immunogenicity Information in Human Prescription Therapeutic Protein and Select Drug Product Labeling - Content and Format Guidance for Industry (Draft) [Internet]. 2022. Available from: https:\/\/www.fda.gov\/media\/155871\/download. Accessed 2022"},{"issue":"10014","key":"1090_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(15)00465-1","volume":"387","author":"I Cleynen","year":"2016","unstructured":"Cleynen I, et al. Inherited Determinants of Crohn\u2019s Disease and Ulcerative Colitis Phenotypes: a genetic association study. Lancet. 2016;387(10014):156\u201367.","journal-title":"Lancet"},{"issue":"10","key":"1090_CR25","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1002\/ijc.29285","volume":"136","author":"A Aureli","year":"2015","unstructured":"Aureli A, et al. HLA-DRB1*13:01 allele in the Genetic Susceptibility to Colorectal Carcinoma. Int J Cancer. 2015;136(10):2464\u20138.","journal-title":"Int J Cancer"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01090-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01090-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01090-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:51:40Z","timestamp":1751637100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01090-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["1090"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01090-1","relation":{},"ISSN":["1550-7416"],"issn-type":[{"type":"electronic","value":"1550-7416"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.) As stated above, authors are employees of Genentech and Roche, and stockholders of Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"107"}}